Literature DB >> 28604347

Treating Psoriasis and Psoriatic Arthritis: Position Paper on Applying the Treat-to-target Concept to Canadian Daily Practice.

Dafna D Gladman1,2, Yves Poulin3,4, Karen Adams3,4, Marc Bourcier3,4, Snezana Barac3,4, Kirk Barber3,4, Vinod Chandran3,4, Jan Dutz3,4, Cathy Flanagan3,4, Melinda J Gooderham3,4, Wayne P Gulliver3,4, Vincent C Ho3,4, Chih-Ho Hong3,4, Jacob Karsh3,4, Majed M Khraishi3,4, Charles W Lynde3,4, Kim A Papp3,4, Proton Rahman3,4, Sherry Rohekar3,4, Cheryl F Rosen3,4, Anthony S Russell3,4, Ronald B Vender3,4, Jensen Yeung3,4, Olga Ziouzina3,4, Michel Zummer3,4.   

Abstract

OBJECTIVE: To develop preliminary treat-to-target (T2T) recommendations for psoriasis and psoriatic arthritis (PsA) for Canadian daily practice.
METHODS: A task force composed of expert Canadian dermatologists and rheumatologists performed a needs assessment among Canadian clinicians treating these diseases as well as an extensive literature search on the outcome measures used in clinical trials and practice.
RESULTS: Based on results from the needs assessment and literature search, the task force established 5 overarching principles and developed 8 preliminary T2T recommendations.
CONCLUSION: The proposed recommendations should improve management of psoriasis and PsA in Canadian daily practice. However, these recommendations must be further validated in a real-world observational study to ensure that their use leads to better longterm outcomes.

Entities:  

Keywords:  ASSESSMENT; PSORIASIS; PSORIATIC ARTHRITIS; TREAT-TO-TARGET

Mesh:

Year:  2017        PMID: 28604347     DOI: 10.3899/jrheum.161473

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  6 in total

Review 1.  Multidisciplinary Management of Psoriatic Arthritis: The Benefits of a Comprehensive Approach.

Authors:  Elisa Visalli; Natascia Crispino; Rosario Foti
Journal:  Adv Ther       Date:  2019-02-25       Impact factor: 3.845

2.  Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study).

Authors:  R Bissonnette; T Luger; D Thaçi; D Toth; A Lacombe; S Xia; R Mazur; M Patekar; P Charef; M Milutinovic; C Leonardi; U Mrowietz
Journal:  J Eur Acad Dermatol Venereol       Date:  2018-03-22       Impact factor: 6.166

3.  Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations.

Authors:  Paolo Gisondi; Marina Talamonti; Andrea Chiricozzi; Stefano Piaserico; Paolo Amerio; Anna Balato; Federico Bardazzi; Piergiacomo Calzavara Pinton; Anna Campanati; Angelo Cattaneo; Paolo Dapavo; Clara De Simone; Valentina Dini; Maria C Fargnoli; Maria L Flori; Marco Galluzzo; Claudio Guarneri; Claudia Lasagni; Francesco Loconsole; Ada Lo Schiavo; Piergiorgio Malagoli; Giovanna Malara; Santo R Mercuri; Maria L Musumeci; Luigi Naldi; Manuela Papini; Aurora Parodi; Concetta Potenza; Francesca Prignano; Franco Rongioletti; Luca Stingeni; Rossana Tiberio; Marina Venturini; Luca Bianchi; Antonio Costanzo; Francesco Cusano; Giampiero Girolomoni; Anna M Offidani; Ketty Peris
Journal:  Dermatol Ther (Heidelb)       Date:  2021-01-11

4.  Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results).

Authors:  Jerry Bagel; John Nia; Peter W Hashim; Manmath Patekar; Ana de Vera; Sophie Hugot; Kuan Sheng; Summer Xia; Isabelle Gilloteau; Elisa Muscianisi; Andrew Blauvelt; Mark Lebwohl
Journal:  Dermatol Ther (Heidelb)       Date:  2018-10-17

Review 5.  Novel Concepts in Psoriatic Arthritis Management: Can We Treat to Target?

Authors:  Laura J Tucker; Weiyu Ye; Laura C Coates
Journal:  Curr Rheumatol Rep       Date:  2018-09-18       Impact factor: 4.592

6.  Safety and effectiveness of secukinumab in psoriasis vulgaris and psoriatic arthritis: Real-world evidence in Japan.

Authors:  Hideki Fujita; Mamitaro Ohtsuki; Akimichi Morita; Ryuji Nagao; Noriko Seko; Kazuko Matsumoto; Yumiko Tani; Tadashi Terui
Journal:  J Dermatol       Date:  2020-10-25       Impact factor: 4.005

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.